His dedicated involvement in trial design has facilitated the advancement of six LCT drugs into clinical trials in the UK, marking significant progress in the quest to alleviate Parkinsons disease worldwide
Cardiac research has demonstrated potential to reduce scar tissue after heart injury
Do you have to inject GHK-Cu peptide
The drug or matching placebo were given for 12 months and the primary endpoint, as shown below, was a motor score used by neurologists (Movement Disorder Scale-Unified Parkinsons Disease Rating Scale) MDS-UPDRS Part III)
risks include gastrointestinal effects, overlapping hepatic metabolism, injection site reactions, and hypoglycaemia, with urgent review required for severe abdominal pain, jaundice, or signs of dehydration